DexTech Medical informs about myeloma study

27 mars, 2023

The company’s Phase 1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) has been initiated and recruitment of patients has begun. The study includesr 20 patients and is initially conducted at three hospitals in Sweden: Karolinska Universite hospital Huddinge, Uddevalla Hospital and Södersjukhuset in Stockholm. Another center in Sweden may be connected later.
The study is expected to be completed in Q4, 2024. Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Division of Hematology/HERM, Karolinska UniversityHospital Huddinge. Analysis of main blood markers takes place at the Central Laboratory, Karolinska UniverSite Hospital Solna, NKS. In accordance with the treatment schedule, OsteoDex is given every two weeks. The inclusion criteria include adult MM patients with relapsed/treatment-resistant disease, who have received 1–3 prior lines of therapy. The primary objective is to confirm safety and tolerability. Secondary objective is to determine treatment response, change in the level of disease-related biomarkers, and documentation of quality of life. The first patient is scheduled to be treated in April 2023.

For more information about DexTech, please contact:
Gösta Lundgren – CFO
DexTech Medical AB
Phone: +46 (0) 707104788

This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on March 27, 2023.

230327 – PR – DexTech – informs about the myeloma study